Trading Signals: IOVA Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 27, 2023)(Iovance Biotherapeutics Inc)
| IOVA latest price $9.4500 (6.78%) ($8.5100 - $9.4500) on Wed. Jan. 2, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.79% (three month average) | RSI | 45 | Latest Price | $9.4500(6.78%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | IOVA advances 3.2% a day on average for past five trading days. | Weekly Trend | IOVA declines -3.2% a week on average for past two weeks. | Market Behavior | Normal for large cap. Value stock rally for small cap. | Correlated ETFs | Broad market will support IOVA advance at 0% a week (0% probability) IBB(49%) XBI(49%) ARKG(48%) IWO(44%) ARKK(42%) | Factors Impacting IOVA price | IOVA will decline at least -2.895% in a week (0% probabilities). VXX(-13%) VIXM(-9%) UUP(-7%) DIA(-5%) TLT(-3%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.895% (StdDev 5.79%) | Hourly BBV | 0 () | Intraday Trend | 7.8% | | | |
|
5 Day Moving Average | $9(5%) | 10 Day Moving Average | $8.64(9.37%) | 20 Day Moving Average | $9.17(3.05%) | To recent high | -20.8% | To recent low | 25.8% | Market Cap | $1.384b | | | | Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA. |